{"id":"W4386570892","doi":"10.1016/j.jtocrr.2023.100572","title":"Patient-Reported Health-Related Quality of Life in KEYNOTE-604: Pembrolizumab or Placebo Added to Etoposide and Platinum as First-Line Therapy for Extensive-Stage SCLC","year":2023,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"ca_institutions":"William Osler Health System; University of Toronto","funders":"Daiichi Sankyo Europe; National Cancer Institute; Chugai Pharmaceutical; Merck Sharp and Dohme; Genentech; Oryzon Genomics; BeiGene; Merck KGaA; Gilead Sciences; GlaxoSmithKline; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Pembrolizumab; Medicine; Placebo; Internal medicine; Lung cancer; Quality of life (healthcare); Hazard ratio; Confidence interval; Etoposide; Oncology; Chemotherapy; Surgery; Cancer; Pathology; Immunotherapy; Nursing","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.01469671,0.0002480171,0.001486031,0.0004227995,0.0002996608,0.00003567653,0.0000917074,0.0002589514,0.00008831003],"category_scores_gemma":[0.06873883,0.0001651486,0.0001746616,0.001166204,0.0007503187,0.00008073738,0.0004472924,0.0009255249,0.00000687068],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001343281,"about_ca_system_score_gemma":0.001973254,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004566618,"about_ca_topic_score_gemma":0.001459821,"domain_scores_codex":[0.9923856,0.0007601757,0.003114372,0.001026534,0.001758997,0.0009543087],"domain_scores_gemma":[0.98994,0.006120223,0.0005985902,0.0007271388,0.001546755,0.001067239],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.1253387,0.001945813,0.7125046,0.003745403,0.001219123,0.006545985,0.005376386,0.00006545038,0.001114703,0.0001061823,0.05722301,0.08481473],"study_design_scores_gemma":[0.01976062,0.01448388,0.941608,0.001144348,0.00002307393,0.0001640862,0.001537155,0.0005479258,0.0004693606,0.001878848,0.01802275,0.0003599936],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9694169,0.001563008,0.000007510103,0.02338636,0.0001789534,0.004967786,0.00003985361,0.00008143618,0.0003582553],"genre_scores_gemma":[0.9880491,0.006109734,0.0001943205,0.000725924,0.0001380365,0.0005180137,0.00004791297,0.00004573489,0.004171183],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2291034,"threshold_uncertainty_score":0.9391056,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.3304689780494397,"score_gpt":0.5523388797000741,"score_spread":0.2218699016506344,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}